Literature DB >> 3025997

Pharmacokinetics of sulbactam/ampicillin in humans: a review.

G Foulds.   

Abstract

The parenteral kinetics of sulbactam, a potent synergist with ampicillin against a broad range of clinically important organisms in humans, are similar to those of ampicillin. The kinetics of ampicillin were not affected by co-administration of sulbactam, and high levels of both agents were attained: 15-min infusions of 2 g of ampicillin plus 1 g of sulbactam produced peak serum concentrations of approximately 120 micrograms of ampicillin/ml plus 60 micrograms of sulbactam/ml; intramuscular injections of 1 g of ampicillin plus 0.5 g of sulbactam produced peak concentrations of 18 micrograms of ampicillin/ml plus 13 micrograms of sulbactam/ml. The drugs had similar half-lives (approximately 1 hr), and both drugs were excreted primarily in the urine (greater than 75%). Although the kinetics of sulbactam in postpartem women and in surgical patients were similar to the kinetics in young men, the half-life of sulbactam (like that of ampicillin) was altered in the elderly, during labor, in neonates, and in patients with renal impairment. After distribution of the agents in the body, the concentrations of both drugs in blister and parenteral fluid were similar to those in serum. Furthermore, useful antibacterial concentrations of both drugs were found in pus, sputum, and middle-ear fluid. The normally low penetration of sulbactam and ampicillin into cerebrospinal fluid was increased in patients with bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025997     DOI: 10.1093/clinids/8.supplement_5.503

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  44 in total

1.  Pharmacokinetics of ampicillin and sulbactam in pediatric patients.

Authors:  M C Nahata; V I Vashi; R N Swanson; M A Messig; M Chung
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Pharmacodynamics of ClpP-Activating Antibiotic Combinations against Gram-Positive Pathogens.

Authors:  Nader Mroue; Anu Arya; Autumn Brown Gandt; Cameron Russell; Angel Han; Ekaterina Gavrish; Michael LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

3.  In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.

Authors:  M D Kitzis; B Ferré; A Coutrot; J F Acar; L Gutmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

4.  Social behaviour involving drug resistance: the role of initial density, initial frequency and population structure in shaping the effect of antibiotic resistance as a public good.

Authors:  I L Domingues; J A Gama; L M Carvalho; F Dionisio
Journal:  Heredity (Edinb)       Date:  2017-06-21       Impact factor: 3.821

5.  Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

7.  Efficacy of prophylaxis with beta-lactams and beta-lactam-beta-lactamase inhibitor combinations against wound infection by methicillin-resistant and borderline-susceptible Staphylococcus aureus in a guinea pig model.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 8.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.

Authors:  George Sakoulas; Warren Rose; Poochit Nonejuie; Joshua Olson; Joseph Pogliano; Romney Humphries; Victor Nizet
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

10.  Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.